In TNFi-exposed patients, a significant (p < 0.05) benefit of abatacept compared with placebo was seen in most subgroups of patients with the defined PPFs at baseline: CRP > ULN, joint erosion score ≥ 3, and presence of dactylitis or enthesitis (Fig. 4). Here, CRP is linked to enthesitis.